Jame Abraham, MD, FACP
banner
jameabraham.bsky.social
Jame Abraham, MD, FACP
@jameabraham.bsky.social
Enterprise Chair, Department of Hematology and Medical Oncology, Cleveland Clinic; Deputy Editor @ASCOPost and JCO Oncology Practice- Opinions are my own - Believes in humanity, science and kindness! #breastcancer doc #Medsky #Oncsky
Pinned
My humble journey 😀🙏🏾
DESTINY 05 trial - in high risk her - 2 positive #breastcancer - 53% reduction in invasive disease free survival with TDXd - @NSABPFoundation @myesmo.bsky.social @oncoalert.bsky.social ! Honored to be part of the study ! @clevelandclinic.bsky.social
October 18, 2025 at 11:07 PM
It was a beautiful and blessed weekend for the Abraham family—our son Abel married Kathryn!
September 17, 2025 at 6:43 PM
From improving efficiency to advancing research, AI is transforming oncology. I joined @Shepard Dale on the @CleClinicMD Cancer Advances podcast to discuss what this means for patients and providers. #CleClinicCancer cle.clinic/41OwRO8
Artificial Intelligence in Oncology
Jame Abraham, MD, Chair of the Department of Hematology & Medical Oncology at Cleveland Clinic Cancer Institute, joins the Cancer Advances Podcast to discuss how artificial intelligence (AI) is transf...
cle.clinic
September 11, 2025 at 9:16 PM
David Baltimore, Nobel-Winning Molecular Biologist, Dies at 87 www.nytimes.com/2025/09/07/s...
David Baltimore, Nobel-Winning Molecular Biologist, Dies at 87
www.nytimes.com
September 8, 2025 at 1:55 AM
It is Bike VeloSano weekend in #cleveland Thank you for coming together to raise money for cancer research @clevelandclinic.bsky.social ! Science and research saves lives !!
September 6, 2025 at 1:07 AM
Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy - The Lancet www.thelancet.com/journals/lan...
Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with a...
Allocation to 5 further years of AIT reduced subsequent distant recurrence rates by about a quarter despite substantial non-adherence. Longer follow-up would have been needed to help assess directly a...
www.thelancet.com
August 14, 2025 at 9:02 PM
We are excited to welcome Dr. Santhosh Rao as the Medical Director of the HemOnc team @ClevelandClinic Akron General! In addition to general oncology - he will be focusing on building a Genito Urinary Medical Oncology Program in @ClevelandClinic Southern Market
August 9, 2025 at 11:33 AM
Pleaase join me in congratulating Nancy Musoke M.D, third year HemOnc Fellow Cleveland Clinic the reciepient of CLL Society’s 2025 Integrative Medicine Award. "Curcumin, Exercise and Placebo Effects on CLL / SLL Progression and Immune Function
July 23, 2025 at 1:33 AM
Human Epidermal Growth Factor Receptor 2 Positivity a Moving Target in the Era of Antibody-Drug Conjugates | JCO Oncology Practice ascopubs.org/doi/10.1200/... @oncoalert.bsky.social
July 14, 2025 at 1:33 AM
Outstanding talk on AI in healthcare by @neilmehtamd.medsky.social @clevelandclinic.bsky.social Artificial intelligence summit!
July 12, 2025 at 11:58 AM
Wonderful to be part of one of the best cancer programs in the country as per @newsweek.com rankings.newsweek.com/americas-bes... @clevelandclinic.bsky.social
June 21, 2025 at 12:06 AM
June 18, 2025 at 1:53 AM
Congratulations to the outstanding group of fellows graduating from @clevelandclinic.bsky.social Hematology and Medical Oncology Department in 2025! We are so proud of them and wish them all the best !!
June 9, 2025 at 9:28 PM
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer @nejm.org @ascocancer.bsky.social @clevelandclinic.bsky.social
June 1, 2025 at 6:05 PM
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer | New England Journal of Medicine www.nejm.org/doi/full/10....
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer | NEJM
Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor for advanced breast cancer....
www.nejm.org
June 1, 2025 at 2:53 PM
Wonderful to be part of the editorial board members of @ascopost.bsky.social ! #1 oncology news paper in the world ! Voice of @ascocancer.bsky.social
June 1, 2025 at 12:02 PM
Thank you @theaacr.bsky.social for your leadership in advocating for cancer research! @ascocancer.bsky.social
May 31, 2025 at 3:55 PM
Looking forward to seeing you at @ascocancer.bsky.social 2025 meeting - please visit @clevelandclinic.bsky.social booth
May 30, 2025 at 1:14 PM
We are looking for exceptional doctors to join our HemOnc team - Ohio/ Florida - if you are attending @ascocancer.bsky.social meeting please reach out jobs.clevelandclinic.org/job/16715724...
May 18, 2025 at 12:53 AM